Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
October 21, 2021Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas MühlerNeurologyPublished: April 14, 2020
